

Appln No. 10/696,900  
Office Action dated January 9, 2006  
Response June 5, 2006

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1 and 2. Cancelled.

**3 (Currently Amended).** A recombinant vector comprising a 5' AAV-1 inverted terminal repeat (ITR) and a heterologous nucleic acid for delivery to a cell selected transgene, wherein said ITR has the sequence selected from the group consisting of:

- (a) nt 1 to 143 of SEQ ID NO: 1;
- (b) ~~a nucleic acid sequence complementary to (a); and~~
- (c) ~~a functional fragment of (a) or (b).~~

**4 (Original).** The recombinant vector according to claim 3, wherein said vector further comprises a 3' AAV-1 ITR.

**5 (Currently Amended).** A recombinant vector comprising a 3' AAV-1 inverted terminal repeat (ITR) and a heterologous nucleic acid for delivery to a cell selected transgene, wherein said ITR has the sequence selected from the group consisting of:

- (a) nt 4576 to 4718 of SEQ ID NO: 1;
- (b) ~~a nucleic acid sequence complementary to (a); and~~
- (c) ~~a functional fragment of (a) or (b).~~

Appln No. 10/696,900  
Office Action dated January 9, 2006  
Response June 5, 2006

6 (Original). The recombinant vector according to claim 5, wherein said vector further comprises a 5' AAV-1 ITR.

Claims 7 and 8. Cancelled.

9 (Currently Amended). The recombinant vector according to claim 3, wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17 or ~~functional fragments thereof~~.

10 (Original). The recombinant vector according to claim 3, wherein said vector further comprises adenovirus sequences.

11 (Original). The host cell transduced with a recombinant viral vector according to claim 3.

Claims 12-16. Cancelled.

17 (Original). A composition comprising a recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 having the amino acid sequence of SEQ ID No: 13; AAV-1 vp2 having the amino acid sequence of SEQ ID NO: 15 and AAV-1 vp3 having the amino acid sequence of SEQ ID NO: 17 and a heterologous molecule which comprises an AAV 5' inverted terminal repeat sequence (ITR), a transgene, and an AAV 3' ITR.

18 (Currently Amended). The composition of claim 17 wherein the AAV-1 protein vp1 is encoded by a nucleic acid having at least ~~about~~ 98% identity to nucleotides 2223-4431 of SEQ ID NO:1, as measured by ~~MacVector 6.0~~ MACVECTOR 6.0™ program at default parameters.

Appln No. 10/696,900  
Office Action dated January 9, 2006  
Response June 5, 2006

**19 (Currently Amended).** The composition of claim 17 wherein the AAV-1 protein vp2 is encoded by a nucleic acid having at least ~~about~~ 98% identity to nucleotides 2634-4432 of SEQ ID NO:1, as measured by ~~MacVector 6.0~~ MACVECTOR 6.0<sup>TM</sup> program at default parameters.

**20 (Currently Amended).** The composition of claim 17 wherein the AAV-1 protein vp3 is encoded by a nucleic acid having at least about 98% identity to nucleotides 2829-4432 of SEQ ID NO:1, as measured by ~~MacVector 6.0~~ MACVECTOR 6.0<sup>TM</sup> program at default parameters.

**21 (Original).** The composition of claim 17 wherein the AAV 5' ITR and 3' ITR are of AAV serotype 2.

**22 (Original).** The composition of claim 21 wherein the recombinant virus further comprises a regulatable promoter which directs expression of the transgene.